The Effects of Different Exercise Modalities in Adolescents With Type 1 Diabetes Using AID Systems
NCT ID: NCT05619198
Last Updated: 2023-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2022-12-19
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The overall objective of this study is to assess the efficacy of the current recommended guidelines for physical activity (PA) in response to acute moderate intensity continous exercise (MICE) and high intensity interval exercise (HIIE) among adolescents with type 1 diabetes (T1D) using automated insulin delivery (AID) systems (MiniMed 780G and Tandem Control-IQ).
Methods:
This study will be a two-period, cross-over, clinical trial with between and within cohort comparisons of two different exercise modalities among a total of 24 age-, sex-, and insulin-dose-matched adolescents with T1D (12 using MiniMed 780G and 12 using Tandem Control-IQ).
Endpoint:
The primary endpoint is sensor-derived time in range (3.9 mmol/L-10.0 mmol/L) around exercise
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Type 1 Diabetes, Exercise and Mentoring Trial
NCT06296992
Exercise in Adolescents With Type 1 Diabetes
NCT04418869
Physical Activity and Glycemic Control in Adolescents
NCT02674828
Competition Induced Hyperglycemia in Athletes With Type 1 Diabetes
NCT05561517
Exercises on Children and Adolescents With Type 1 Diabetes Mellitus (T1DM)
NCT06680557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will undertake two exercise visits each including a bout of exercise on a stationary bicycle of either one of two exercise modalities; i.) high-intensity interval exercise with sprints at \~85% of VO2max (HIIE); ii.) moderate intensity continuous exercise at \~60% of VO2max (MICE).
Participants will arrive at the research facility, Steno Diabetes Center Copenhagen, in the afternoon. As per the current recommended guidelines, the MICE-session will be announced to the AID systems 60 minutes in advance, whereas the HIIE-session will not be announced. Participants will have a canula placed in a antecubital vein for plasma sampling.
Participants will rest for 60 minutes, exercise for 45 minutes and rest again for 75 minutes before leaving the research facility. During exercise participants will be fitted with a spirometry face mask to compute ventilatory thresholds and indirect calorimetry (Vyaire Vyntus® CPX, Intramedic A/S) and a telemetry chest strap (Polar H10) for integrated HR heart rate (HR) measurements with the spirometry device.
In the MICE session: After 15 minutes post-exercise rest the temporary target/exercise mode is turned off.
Around each study visit (24 hours prior until 24 hours after), sensor glucose as well as sleep and physical activity will be recorded. Sensor glucose will be measured by participants' own devices. Sleep and physical activity level will be assessed with a wrist-worn accelerometer, ActiGraph wGT3X-BT (ActiGraph, Pensacola, FL).
Study days will be separated by at least three days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Intensity Interval Exercise
Plasma and sensor glucose is monitored before, during and after a bout of high intensity interval exercise
High Intensity Interval Exercise
High Intensity Interval Exercise:
* 5 minutes resting phase @ 0 watts.
* 5-minute warm up phase @ 20 watts.
* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.
* 5 minutes resting phase @ 0 watts.
Moderate Intensity Continous Exercise
Plasma and sensor glucose is monitored before, during and after a bout of moderate intensity continous exercise
Moderate Intensity Continous Exercise
Moderate Intensity Continous Exercise:
* 5 minutes resting phase @ 0 watts.
* 5-minute warm up phase @ 20 watts.
* 40 minutes of MICE 65% VO2max.
* 5 minutes resting phase @ 0 watts.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High Intensity Interval Exercise
High Intensity Interval Exercise:
* 5 minutes resting phase @ 0 watts.
* 5-minute warm up phase @ 20 watts.
* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.
* 5 minutes resting phase @ 0 watts.
Moderate Intensity Continous Exercise
Moderate Intensity Continous Exercise:
* 5 minutes resting phase @ 0 watts.
* 5-minute warm up phase @ 20 watts.
* 40 minutes of MICE 65% VO2max.
* 5 minutes resting phase @ 0 watts.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 1 diabetes \> 1 year
* Use of Tandem t:slim X2 Control-IQ or Medtronic MiniMed 780G with connected continous glucose monitor \> 3 months
* HbA1c below 75 mmol/L
Exclusion Criteria
* Breastfeeding, pregnancy or planning to become pregnant
* Lack of compliance with key study procedures at the discretion of the investigator
13 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steno Diabetes Center Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Lindkvist, MD
Role: PRINCIPAL_INVESTIGATOR
Steno Diabetes Center Copenhagen, Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Steno Diabetes Center Copenhagen
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MODE2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.